# Liquidia Corporation (LQDA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $68.66, market value $6.1 billion.

## Valuation
- **P/E (trailing): 49.0×**. Liquidia Corporation trades at 49.0× trailing earnings. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 12.2×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.24**. A PEG of 0.24 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 13.6×**. Each dollar of revenue is priced at 13.6×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 31.4×**. The shares trade at 31.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 35.1×**. Enterprise value is 35.1× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.5%** (5-yr avg -7.8%). Free cash flow equals 2.5% of the market value, above its five-year average of -7.8%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.0%**. The inverse of the P/E: 2.0% of the price is earned each year.

## Profitability
- **Operating margin: 37.4%**. 37.4% of revenue is left after running the business, an exceptional level.
- **Net margin: -43.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: -154.0%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -105.6%**. Return on all capital, debt included, is -105.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 42.3%**. Each dollar of assets produces 42.3% of profit.

## Growth
- **Revenue growth (1 yr): 1031.2%** (3-yr 115.0%/yr, 5-yr 192.5%/yr). Revenue grew 1031.2% over the last year, against 192.5% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 50.9%**. Earnings per share rose 50.9%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.44**. Debt is 0.44 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Liquidia Corporation holds more cash than debt.
- **Current ratio: 2.01** (quick 2.01). Current assets cover the next year's liabilities 2.01 times.
- **Altman Z-score: 13.68**. A Z-score of 13.68 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Liquidia Corporation does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 138.1%** (YTD 99.1%, 3-mo 11.0%). The shares are up 138.1% over twelve months including dividends.
- **From 52-week high: -26.7%** (224.6% above the low). Trading 27% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 40**. An RSI of 40 is neutral.
- **Beta (1 yr): 0.98** (volatility 66%). Beta of 0.98 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LQDA · Page: https://foliofundamentals.com/stocks/lqda

Not investment advice.